• Attendees: 150–250

• Academic vs. industry ratio: ~30% academic / 70% industry

• Abstract deadline: Closed (event has occurred)

• Early-bird registration: Closed (event has occurred) 
  
  

• E3 ligase deep dives: Substrate specificity, structural determinants of ternary complex formation, and E3 hijacking mechanisms

• European biotech perspectives: Updates across LYTACs, PROTABs, AUTACs, and other modalities for extracellular and membrane protein degradation

• Workshop-style sessions (agenda-dependent): Case-study discussions on degrader design and decision-making 
  

Advances in PROTACs, molecular glues, E3 ligase biology, and next-generation degrader platforms. Strong representation of extracellular and autophagy-based degrader modalities. Audience: Mix of European biotech/pharma discovery teams and academic labs with TPD programs. 

Industry-focused deep dive on molecular glue discovery, target selection frameworks, screening strategies, and clinical translation. Expect case studies from companies advancing glues into the clinic and panels on intellectual property, E3 ligase selectivity, and assay development. The meeting distinguishes between neosubstrate-recruiting molecular glues (IMiD-like mechanisms) and bifunctional induced-proximity degraders. 

Primarily industry (pharma and biotech discovery/development teams), with strong medicinal chemistry and structural biology representation. 

• Attendees: 250–350

• Academic vs. industry ratio: ~15% academic / 85% industry

• Abstract deadline: Closed (event has occurred)

• Early-bird registration: Closed (event has occurred)  

• Clinical-stage program updates: Expect updates and lessons from first-in-human studies, including resistance mechanisms and pharmacodynamic biomarker strategies

• IP strategy panels: Navigating the patent landscape for PROTAC linkers, E3 ligase recruiters, and molecular glue scaffolds

• E3 ligase diversity: Emerging E3s beyond VHL/CRBN (commonly including DCAF15, DCAF16, RNF4, RNF114, and VHL variants)

• Poster sessions: Often feature unpublished industry data; scan early for emerging E3 ligases, non-oncology indications, and novel glue scaffolds 
  

• Expected attendees: 250–350 (Keystone meetings are typically capped)

• Academic vs. industry ratio: ~50% academic / 50% industry

• Abstract deadline: Check organizer site

• Early-bird registration: Check organizer site
  

• Late-breaking short talks: Often surface high-impact data ahead of publication

• Cryo-EM structural sessions: Ternary complex structures, cooperativity, induced-fit changes, and unexpected substrate engagement

• Workshops on emerging modalities: Transcription factor degraders, RIBOTACs, AUTACs, DUB-centered strategies, and targeted chromatin modulation

• Poster sessions: High discussion depth due to the multi-day, on-site format 
  
  

Fundamental and translational induced proximity science spanning degraders, molecular glues, stabilizers, transcription factor degraders, RNA-targeting chimeras (RIBOTACs), and emerging modalities. Strong academic representation and mechanistic biology, with sessions bridging ubiquitin biology, phase separation, and allosteric mechanisms. 

Roughly 50/50 academic and industry; expect cell biologists, chemical biologists, structural biologists, and medicinal chemists.

• Expected attendees: 250–350

• Academic vs. industry ratio: ~20% academic / 80% industry

• Abstract deadline: Typically 4–6 weeks before the event (confirm on organizer site)

• Early-bird registration: Typically closes 6–8 weeks before the event (confirm on organizer site)
  

• Extracellular degrader sessions: LYTACs, AbTACs, PROTABs, and related modalities for secreted/membrane targets

• ADME & developability panels: Oral exposure vs. cellular permeability, formulation constraints for beyond-rule-of-5 compounds, and CMC realities

• Hook effect mitigation: Mechanistic understanding and SAR tactics to widen the window

• Linker-free/minimalist designs: Strategies to reduce molecular weight and improve properties 
  
  

Europe’s established proximity therapeutics forum spanning degraders, molecular glues, stabilizers, and extracellular degraders. Strong focus on translational challenges, ADME/PK, cellular permeability, and screening platforms; increasing coverage of autophagy-based and RNA-targeting modalities.

Industry-heavy (European and US pharma/biotech), with sessions tailored to discovery, early development, and platform technology teams.

• Expected attendees: 800–1,200 (across all tracks)

• Academic vs. industry ratio: ~25% academic / 75% industry

• Abstract deadline: Typically closes ~8–10 weeks before the event (confirm on organizer site)

• Early-bird registration: Typically closes ~8–10 weeks before the event (confirm on organizer site) 
  

Broad medicinal and biophysical chemistry meeting with dedicated TPD programming (including the CHI degrader tracks below). Emphasis on hit-to-lead optimization, fragment-based design, structure-based drug design, and biophysical characterization of challenging targets. 

Medicinal chemists, computational chemists, biophysicists, and assay scientists from pharma, biotech, and CROs. 

• Biophysical characterization sessions: NMR, cryo-EM, ITC, SPR, BLI applied to ternary complexes (cooperativity, stoichiometry, kinetics)

• Computational approaches: AI/ML and physics-based modeling for ternary complex prediction and linker design

• Exhibition hall: Screening technologies, compound libraries (including degrader-focused DELs), and CRO capabilities 
  
  

• Expected attendees: 150–250 (track-specific)

• Academic vs. industry ratio: ~30% academic / 70% industry

• Abstract deadline: Typically closes ~8–10 weeks before the event (confirm on organizer site)

• Early-bird registration: Typically closes ~8–10 weeks before the event (confirm on organizer site)
  

Assays, screening strategies, and early discovery approaches for targeted degradation and induced proximity: target selection, E3 ligase prioritization, ternary complex assays, hit identification, and proteomics-based validation. 

• Assay technology deep dives: TR-FRET, AlphaLISA, NanoBRET, plus orthogonal methods (MST, SPR, BLI) for cooperativity and stoichiometry

• Proteomics-based profiling: Off-targets, neosubstrates (for glues), degradation kinetics (Dmax, DC50), and substrate motif discovery

• Cellular target engagement: CETSA, NanoBRET TE, and live-cell validation strategies

• DEL case studies: Binder-to-degrader triage and follow-up validation cascades ​
  
  

Medicinal chemists, computational chemists, biophysicists, and assay scientists from pharma, biotech, and CROs. 

• Expected attendees: 150–250 (track-specific)

• Academic vs. industry ratio: ~25% academic / 75% industry

• Abstract deadline: Typically closes ~8–10 weeks before the event (confirm on organizer site)

• Early-bird registration: Typically closes ~8–10 weeks before the event (confirm on organizer site)

• Linker chemistry & SAR: Exit vector optimization, linker length/flexibility, and minimalist/linker-reduced approaches 

• Cellular permeability vs. oral bioavailability: Practical strategies (passive diffusion, transport, formulation) for beyond-rule-of-5 degraders

• Hook effect mitigation: Mechanism-driven SAR to avoid U-shaped dose responses

• Kinetics-first optimization: Using Dmax, DC50, and degradation half-life to prioritize leads beyond kD 

• Emerging modalities: Homo-bifunctional designs, RIBOTACs, DUB-centered strategies, and autophagy-targeting chimeras (AUTACs) 

Medicinal chemists, computational chemists, biophysicists, and assay scientists from pharma, biotech, and CROs. 

Lead optimization and translation: linker design, E3 selectivity, cellular permeability, oral exposure, and next-generation modalities and screening approaches. 

• Expected attendees: 150–250 

• Academic vs. industry ratio: ~75% academic / 25% industry

• Abstract deadline: Typically closes ~6–8 weeks before the event (confirm on organizer site)

• Early-bird registration: Typically closes ~6–8 weeks before the event (confirm on organizer site)
  

• E3 ligase mechanism talks: Substrate recognition, receptor domains, chain topology, and allosteric regulation 

• Ubiquitin linkage selectivity: K48, K11, K63, K27, K29, K33, plus mixed/branched chains and their cellular consequences

• DUB biology: Substrate and chain-type selectivity, localization, and how DUBs modulate degradation pathways

• Proteasome and autophagy mechanisms: Proteasome architecture, p97/VCP biology, and autophagy receptor pathways 

Primarily academic cell biologists, structural biologists, and biochemists; smaller industry presence than drug discovery-focused meetings. 

Ubiquitin and ubiquitin-like (Ubl) biology, proteasome function, autophagy, and protein degradation systems. Foundational science that increasingly matters as TPD expands beyond proteasomal degradation. 

• Expected attendees: 150–200 

• Academic vs. industry ratio: ~45% academic / 55% industry

• Abstract deadline: Typically closes ~8–10 weeks before the event (confirm on organizer site)

• Early-bird registration: Typically closes ~8–10 weeks before the event (confirm on organizer site)

• Young investigator talks: Often surface novel chemistry and emerging biology early

• ADME/PK sessions: Practical, failure-inclusive optimization lessons (permeability, efflux, metabolic stability)

• Resistance mechanisms: E3 ligase mutations, proteasome alterations, and compensatory pathways

• IP landscape discussions: Particularly useful for academic groups and SMEs planning partnerships

• Smaller-scale networking: High signal-to-noise for collaboration building 

Mix of UK/European academics, biotech, and pharma discovery teams; particularly strong medicinal chemistry community. 

Multidisciplinary TPD meeting spanning design, biology, chemistry, ADME, and translation across PROTACs, molecular glues, and beyond. Strong UK/European academic and SME presence, with a workshop-style format and candid scientific discussion. 

• Track it for late-year program updates and platform announcements 

• Translational sessions (biomarkers, PK/PD, resistance) if on the agenda

• Assay/screening case studies and vendor technology showcases

• Boston-based networking (often high density of TPD teams) 
  

Industry-heavy with invited academic speakers. 

Major US industry forum for targeted protein degradation and induced proximity across discovery, screening, and translation.